Liaoning Cheng Da Co., Ltd. operates within the Drug stores and proprietary stores sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Liaoning Cheng Da Co., Ltd. with three other
companies in this sector in CHINA :
LBX PHARMACY CHAIN JSC
sales of 11.66 billion Chinese Renmimbi [US$1.67 billion]
of which 88%
was Pharmaceutical retail),
Dashenlin Pharmaceutical Group Co Ltd
(11.14 billion Chinese Renmimbi [US$1.60 billion]
of which 125%
was South China), and
Yixintang Pharmaceutical Group Co Ltd
(10.48 billion Chinese Renmimbi [US$1.50 billion]
of which 95%
was Retail Sale).
During the year ended December of 2019, sales at
Liaoning Cheng Da Co., Ltd. were 17.75 billion Chinese Renmimbi (US$2.54 billion).
decrease of 7.9%
versus 2018, when the company's sales were 19.28 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 12.5% decline
in Trade, from 14.65 billion Chinese Renmimbi to 12.81 billion Chinese Renmimbi.
There were also decreases in sales in
Medicines Sales (down 3.0% to 2.94 billion Chinese Renmimbi)
Headquarter Office (down 7.3% to 11.47 million Chinese Renmimbi)
However, these declines were partially offset by the increase in sales of
Drugs Manufacturing (up 20.6% to 1.68 billion Chinese Renmimbi)
Energy Research (up 53.3% to 303.59 million Chinese Renmimbi)